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INTRODUCTION
Dermatomyositis (DM) is an idiopathic inflammatory
myopathy with characteristic cutaneous manifestations (1).
It is strongly associated with malignancy, which is diagnosed
in about 25% of DM patients above the age of 50. Malig-
nant disease may occur before the onset of myositis, concur-
rently, or afterward. The most commonly observed cancers
in patients with DM are breast and gynecological cancers
among women, lung cancer among men, and gastrointesti-
nal malignancies in both sexes (2, 3).
A small number of cancers first appear in one or more me-
tastatic sites, and the primary site is not known despite full
evaluation. So it is called cancer of unknown primary site
(CUPS). CUPS is present in 5-10 percent of all malignancies.
Although many malignancies are associated with DM,
CUPS has not been reported to be associated with DM to
the best of our knowledge. We report here on the first case
of CUPS associated with DM. 
CASE REPORT
A 62-yr-old woman visited our hospital and presented to
us with hip pain. She was a nonsmoker, not addicted to alco-
hol, and she had no significant past gynecological or family
history. Physical examination showed painful tenderness and
swelling on the left gluteal lesion along the lower extremi-
ties. Laboratory findings revealed no significant abnormali-
ties including tumor markers, such as CA-125, CEA. Chest
radiogragh showed no mass-like lesion or infiltration. A com-
puted tomographic scan of the pelvis revealed a large lobu-
lated mass in left iliopsoas muscle (Fig. 1). Multiple lympha-
denophathies were shown in the paraaortic and left common
iliac chain. For confirmative diagnosis, she received biopsy on
the iliopsoas mass. The tissue showed metastatic, well differ-
entiated squamous cell carcinoma. For the evaluation of the
primary site, she received chest computed tomography, eso-
phagogastroscopy, anoscopy, gynecologic examination, and
positron emission tomography. These intensive workup reve-
aled no specific findings except for positron emission tomog-
raphy, which revealed hypermetabolic lesions in the iliop-
soas muscle with regional lymph nodes. However, the pri-
mary site was not identified. We concluded the diagnosis as
CUPS and planned to perform palliative chemoradiotherapy
for the iliopsoas mass. However, her general condition was
poor, with a Easten Co-operative Oncology Group (ECOG)
score of 3, so she just received opioid for pain management
at an outpatient clinic.
Two weeks after diagnosis, she was admitted to hospital
because of facial edema, shoulder pain, dysphagia, and pro-
gressive weakness of the proximal muscles of her upper and
lower limbs. Her performance status score was ECOG 4 due
to pain and weakenss. Physical examination showed the he-
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Dermatomyositis Associated with Cancer of Unknown Primary Site
Dermatomyositis (DM) is an uncommon inflammatory myopathy with characteris-
tic rash accompanying, or more often preceding, muscle weakness. There is a well-
recognized association between DM and several cancers, such as ovarian cancer,
breast cancer, melanoma, colon cancer, and non-Hodgkin lymphoma. We report
the first case of cancer of unknown primary site associated with DM. A 62-yr-old
woman presented to us with both shoulder painful swelling and facial edema. She
was diagnosed previously as cancer of unknown primary site, histologically con-
firmed with squamous cell carcinoma in a pelvic mass. For the following days, she
complained of erythematous face followed by progressive weakness of the proxi-
mal muscles of upper and lower limbs. The laboratory tests showed an increased
muscle enzyme and acute phase reactants. The electromyogram showed the typi-
cal findings of DM. After the treatment with high dose steroid and methotrexate,
the proximal motor weakness improved, and she received palliative radiation ther-
apy. 
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liotropic discoloration of the eyelids with periorbital edema,
red, violaceous, nonpurpuric skin rash (Gottron’s sign) on the
interpharyngeal joints, face, neck, anterior chest, and arms
(Fig. 2).
The characteristic clinical pictures of DM were supported
by several laboratory abnormalities: increases in creatine kinase
of 5,835 U/L (normal range, 30-225), serum myoglobin of
681 ng/mL (normal range, 0-65), serum lactate dehydroge-
nase of 639 U/L (normal range, 100-220), and erythrocyte
sedimentation rate of 66 mm/hr (normal range, 0-20). Anti-
nuclear antibodies, anti-Jo-1 antibody, anti-RNP antibody,
anti-Ro antibody, and anti-La antibody were negative. These
data could rule out primary autoimmune disease. To exclude
skin metastasis, she received biopsy from the violaceous skin
for histologic examination, which demonstrated pericapil-
lary inflammation. Electromyographic examination revealed
myopathic and neurologic abnormalities (fibrillations, poly-
phasic motor unit potentials of low amplitude, and short
duration) compatible with myositis. The diagnosis was con-
firmed as DM based on the typical skin rash, proximal mus-
cles weakness, elevated levels of serum muscle enzymes, and
electromyogram showing a myopathic pattern. She was treat-
ed with 60 mg/day of prednisone intravenously immediately
after diagnosis. She showed the improvement in skin lesions
and muscle weakness as well as reduction of muscle enzyme.
After treatment with prednisone (60 mg/day) for 2 weeks,
she received additional methotrexate (7.5 mg/week) and ste-
roid at a tapered dose and she showed improvement in the
swallowing and muscular weakness of lower limbs. Four
weeks after the initiation of treatment, she could start radia-
tion therapy at an out-patient clinic and showed relatively
good general condition, with a score of ECOG 2. Restaging
workup after radiation therapy (total 7,000 cGy) showed
nearly complete response. Currently, she has received low
dose steroid (7.5 mg/day) and methotrexate (7.5 mg/week),
and we are planning palliative chemotherapy.
DISCUSSION
The association between malignancy and DM has revealed
that the cancer rate in DM was five to seven times higher than
Fig. 1. Abdominopelvic CT showed a large lobulated mass with
speckled calcification in left iliopsoas muscle.
Fig. 2. The submitted specimen disclosed squamous differentiation of tumor cells scattered dyskeratotic tumor cells, necrotic surface and
keratotic debris. H&E stain ×100 (A), ×200 (B).
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that of the general population (4). Kim et al. already report-
ed about 10% of dermatomyositis/polymyositis patients asso-
ciated with malignancy (5).
Cancer can be diagnosed before, at the time when the can-
cer first becomes obvious, or after the diagnosis of myositis
with a peak incidence occurring within the two-year period
before and after the development of myositis (6, 7). The high-
est risk for developing subsequent tumors is within a short
period after diagnosis of DM (8).
The etiology of DM in patients with cancer is poorly under-
stood. Proposed mechanisms include: common environmen-
tal factors such as virus, a drug, or a chemical, triggering
both cancer, and myositis in a genetically predisposed host,
an immune complex or cellular immune reaction involving
tumor antigens cross-reacting with both muscle and skin
antigens, tumor myotoxin or other products causing muscle
and skin inflammation, and both the tumor and myositis
resulting from a subtle host abnormality of humoral and
cellular immunity (9, 10). In this case, CUPS preceded the
development of DM, and this temporal relation suggests a
paraneoplastic syndrome. It has been noted that DM improves
after the treatment of cancer, with muscle weakness resum-
ing at the relapse of the malignant disease. 
The management of malignancy-associated DM includes
steroids and/or azathioprine as an alternative and steroid-
sparing agent. However, DM associated with cancer is gen-
erally more resistant to corticosteroid and cytotoxic therapies
compared to idiopathic myositis. The activity of DM can
reflect the state of the underlying malignancy. Effective anti-
tumor treatment may be accompanied by regression of the
inflammation, and conversely, it may deteriorate with pro-
gressive malignant disease (11). 
A wide variety of cancers have been reported in patients
with DM. Compared with the general population, lung,
breast, colon, pancreas, and gynecologic tumors were more
common in DM (12-15). Especially, women constitute two-
thirds of DM patients with malignancy, and most of the ma-
lignancies were of the female genital tract with epithelial
ovarian carcinoma predominating (16). In consideration of
histologic subtypes of dermatomyositis associated with can-
cer, Hill et al. reported that adenocarnicoma was the most
common histologic subtype (3). 
To our knowledge, the association between DM and CUPS
has not been reported previously. In this case, the first man-
ifestation of proximal muscle weakness was overlooked as
general weakness associated with cancer progression. How-
ever, typical skin rash and elevated muscle enzyme were the
clue to the diagnosis. The improvement of performance sta-
tus after treatment of DM enabled complete radiation ther-
apy and the better clinical outcome. 
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